Market Closed -
Nasdaq
16:00:00 2024-04-26 EDT
|
5-day change
|
1st Jan Change
|
51.92
USD
|
+1.05%
|
|
+0.52%
|
-6.45%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,359
|
2,882
|
2,767
|
-
|
-
|
Enterprise Value (EV)
1 |
1,104
|
2,180
|
2,109
|
2,208
|
1,765
|
P/E ratio
|
-5.97
x
|
-37.8
x
|
-24.4
x
|
-25.6
x
|
-19.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
26.1
x
|
32
x
|
27.2
x
|
31.1
x
|
EV / Revenue
|
-
|
19.8
x
|
24.4
x
|
21.7
x
|
19.9
x
|
EV / EBITDA
|
-5.81
x
|
-24.8
x
|
-46.2
x
|
-19.1
x
|
-13.8
x
|
EV / FCF
|
-10.9
x
|
11.7
x
|
-25
x
|
-23
x
|
-24.4
x
|
FCF Yield
|
-9.2%
|
8.54%
|
-4%
|
-4.34%
|
-4.1%
|
Price to Book
|
-
|
5.98
x
|
4.14
x
|
4.22
x
|
3.2
x
|
Nbr of stocks (in thousands)
|
43,854
|
51,929
|
53,290
|
-
|
-
|
Reference price
2 |
30.98
|
55.50
|
51.92
|
51.92
|
51.92
|
Announcement Date
|
23-03-29
|
24-02-28
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
110.3
|
86.5
|
101.6
|
88.91
|
EBITDA
1 |
-
|
-63.98
|
-189.9
|
-87.84
|
-45.68
|
-115.8
|
-128.1
|
EBIT
1 |
-
|
-65.02
|
-191.3
|
-89.88
|
-116.3
|
-142.2
|
-163.6
|
Operating Margin
|
-
|
-
|
-
|
-81.47%
|
-134.47%
|
-140%
|
-184.06%
|
Earnings before Tax (EBT)
1 |
-32.1
|
-
|
-188.7
|
-70.03
|
-111.5
|
-132.5
|
-154.5
|
Net income
1 |
-32.1
|
-64.97
|
-188.7
|
-70.69
|
-106.4
|
-122.2
|
-143
|
Net margin
|
-
|
-
|
-
|
-64.08%
|
-123.01%
|
-120.31%
|
-160.88%
|
EPS
2 |
-
|
-145.6
|
-5.190
|
-1.470
|
-2.128
|
-2.029
|
-2.722
|
Free Cash Flow
1 |
-
|
-
|
-101.6
|
186.1
|
-84.28
|
-95.84
|
-72.3
|
FCF margin
|
-
|
-
|
-
|
168.73%
|
-97.44%
|
-94.37%
|
-81.32%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22-01-14
|
22-03-24
|
23-03-29
|
24-02-28
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
17.91
|
14.3
|
14.96
|
63.15
|
20.67
|
19.82
|
20.07
|
20.54
|
15.73
|
EBITDA
|
-
|
-
|
-32.46
|
-93.54
|
-39.59
|
-30.02
|
-29.06
|
-44.42
|
15.72
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-20.7
|
-32.44
|
-32.61
|
-93.88
|
-40
|
-30.46
|
-29.56
|
-44.86
|
15
|
-31.12
|
-33.64
|
-35.03
|
-39.52
|
-42.74
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-170.04%
|
-206.68%
|
-299.94%
|
23.75%
|
-150.57%
|
-169.68%
|
-174.6%
|
-192.42%
|
-271.73%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-32.09
|
-92.87
|
-38.99
|
-27.02
|
-24.14
|
-39.34
|
20.47
|
-27.68
|
-29.85
|
-31.4
|
-35.94
|
-38
|
Net income
1 |
-20.67
|
-32.38
|
-32.09
|
-92.87
|
-38.99
|
-27.34
|
-23.85
|
-39.34
|
19.84
|
-27.71
|
-29.88
|
-31.42
|
-35.95
|
-38
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-152.66%
|
-166.79%
|
-262.99%
|
31.42%
|
-134.07%
|
-150.75%
|
-156.61%
|
-175.06%
|
-241.63%
|
EPS
2 |
-39.85
|
-1.560
|
-0.8800
|
-2.120
|
-0.7600
|
-0.5800
|
-0.5000
|
-0.8100
|
0.4200
|
-0.5488
|
-0.5788
|
-0.6075
|
-0.6738
|
-0.6100
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22-03-24
|
22-05-12
|
22-08-15
|
22-11-14
|
23-03-29
|
23-05-08
|
23-08-14
|
23-11-13
|
24-02-28
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
255
|
702
|
658
|
558
|
1,002
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-102
|
186
|
-84.3
|
-95.8
|
-72.3
|
ROE (net income / shareholders' equity)
|
-
|
-80%
|
-452%
|
-20.5%
|
-4%
|
-15.6%
|
-9.76%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
-
|
9.280
|
12.60
|
12.30
|
16.20
|
Cash Flow per Share
2 |
-
|
-122.0
|
-2.730
|
4.320
|
-1.050
|
1.900
|
-
|
Capex
1 |
-
|
5.78
|
2.28
|
21.4
|
12.9
|
13.1
|
19
|
Capex / Sales
|
-
|
-
|
-
|
19.42%
|
14.92%
|
12.91%
|
21.33%
|
Announcement Date
|
22-01-14
|
22-03-24
|
23-03-29
|
24-02-28
|
-
|
-
|
-
|
Last Close Price
51.92
USD Average target price
80.31
USD Spread / Average Target +54.68% Consensus |
1st Jan change
|
Capi.
|
---|
| -6.45% | 2.77B | | +1.51% | 42.75B | | +48.15% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|